Sutro Biopharma Inc. (STRO)
STRO trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1382101/000119312526119873/0001193125-26-119873-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | STRO on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2018 |
| SEC CIK | 0001382101 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DELAWARE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $102.5M |
| Net income | -$191.1M |
| Operating income | -$158.4M |
| Net margin | -186.5% |
| Operating margin | -154.5% |
| Revenue growth | +65.2% |
| Cash | $58.1M |
| Total assets | $173.8M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 1.5× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-12 |
| Cash and burn | $46.9M cash; operating cash flow -$32.4M a quarter. | Report 2026-09-30 |
| Shares outstanding | 16,601,411 (2026-11-06); 85,135,290 a year earlier; 60,953,204 three years earlier. 1y figure adjusted for split (1-for-10 overall); 3y figure adjusted for split (1-for-10 overall). | Cover page 2026-11-06 |
| Reverse splits, 3 years | 1; latest 1-for-10 on 2025-12-03 | Source 2025-12-03 |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the market | Latest 2026-02-10 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ernst & Young LLP, San Mateo, California, United States | PCAOB Form AP 2026-04-02 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $90K, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $9.1M | -$31.5M | -$22.5M | $46.9M | No debt tags | $45.1M | 10-Q 2026-11-12 |
| Q2 2026 2026-06-30 | $9.8M | -$38.5M | -$38.3M | $54.3M | No debt tags | $45.7M | 10-Q 2026-08-12 |
| Q1 2026 2026-03-31 | $14.5M | -$38.5M | -$42.3M | $73.7M | No debt tags | $99.6M | 10-Q 2026-05-14 |
| Q4 2025 2025-12-31 | $11.6M | -$46.8M | -$26.4M | $58.1M | No debt tags | $102.5M | 10-K 2026-03-23 |
| Q3 2025 2025-09-30 | $9.7M | -$56.9M | -$38.2M | $65.9M | No debt tags | $105.6M | 10-Q 2026-11-12 |
| Q2 2025 2025-06-30 | $63.7M | -$11.5M | -$44.7M | $64.0M | No debt tags | $104.5M | 10-Q 2026-08-12 |
| Q1 2025 2025-03-31 | $17.4M | -$76.0M | -$67.9M | $106.2M | No debt tags | $66.4M | 10-Q 2026-05-14 |
| Q4 2024 2024-12-31 | $14.8M | -$72.4M | -$71.7M | $190.3M | No debt tags | $62.0M | 10-K 2026-03-23 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2026-04-01 |
| Latest annual report | 10-K | 2026-03-23 |
| Latest quarterly / interim | 10-Q | 2026-11-12 |
| Latest current report | 8-K | 2026-11-12 |
| Latest proxy | DEFA14A | 2026-04-22 |
Source: SEC EDGAR submissions feed, 628 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +2.1% |
| 1 month | -10.8% |
| 3 months | -53.9% |
| Year to date | -15.1% |
| 1 year | +5.6% |
| From 52-week high | -76.0% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| IPHA | Innate Pharma S.A. ADS | $1.41 | -1.06% | $156.9M |
| IVVD | Invivyd Inc. | $0.5377 | -7.63% | $158.5M |
| HUMA | Humacyte Inc. | $0.5403 | -3.24% | $150.1M |
| TARA | Protara Therapeutics Inc. | $2.38 | -5.93% | $146.5M |
| FATE | Fate Therapeutics Inc. | $1.14 | -10.94% | $138.6M |
| PALI | Palisade Bio Inc. | $1.03 | -8.04% | $184.7M |
| ENGN | enGene Therapeutics Inc. | $1.89 | -21.58% | $126.7M |
| CRDL | Cardiol Therapeutics Inc. Class A Common Shares | $0.9798 | -2.02% | $125.1M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier